Amgen’s Strategic Crossroads: Innovation Meets Intensifying Competition

The biotechnology giant Amgen finds itself navigating a complex landscape where groundbreaking innovation collides with mounting competitive pressures. While the company faces imminent challenges from newly approved biosimilar drugs targeting its key products, it simultaneously advances a promising pipeline of novel therapies that could redefine its future growth trajectory.

Competitive Pressures Mount with FDA Biosimilar Approvals

Significant headwinds have emerged for Amgen following the U.S. Food and Drug Administration’s approval of BILDYOS® and BILPREVDA®, biosimilar alternatives to Amgen’s blockbuster medications Prolia and Xgeva. This regulatory decision signals the beginning of intensified competition within the global denosumab market, which addresses osteoporosis and cancer-related bone complications.

Market analysts anticipate this development will inevitably create pricing pressures and erode Amgen’s market share for these established revenue generators. Although the company had previously factored this competitive threat into its second-quarter projections, the materialization of these biosimilars presents tangible challenges to maintaining dominance in this therapeutic area.

Promising Pipeline Offsets Near-Term Challenges

Counterbalancing these competitive threats, Amgen demonstrates considerable strength through its innovative drug development program. The experimental obesity treatment MariTide has generated substantial interest following early study results showing potential weight loss of up to 20 percent. This positioning could prove transformative in the rapidly expanding obesity medication market, estimated at $150 billion. Critical Phase 2 trial data expected later this year will provide clearer indications of the drug’s commercial potential.

Should investors sell immediately? Or is it worth buying Amgen?

In another significant development, Royalty Pharma has committed up to $950 million to secure a stake in Amgen’s cancer drug Imdelltra. The first DLL3-targeting therapy for lung cancer has demonstrated impressive commercial traction, generating $215 million in revenue during the first half of 2025 despite its recent regulatory approval.

Strategic Initiatives to Accelerate Development

Amgen is further advancing its transformation through a strategic partnership with Veeva Systems designed to optimize clinical trial processes and accelerate drug development timelines. This collaboration represents a strategically astute move in an industry where speed to market increasingly determines competitive advantage.

Amgen shares have reflected this mixed outlook, trading cautiously as investors weigh near-term risks against long-term opportunities. Market participants await additional insights from the company’s upcoming presentation at the Wells Fargo Healthcare Conference this Wednesday, where management is expected to detail its strategic response to the evolving biosimilar competitive landscape.

The fundamental question remains whether Amgen will enter a period of consolidation or embark on new growth trajectories. The answer may become clearer as MariTide data emerges in the coming months, potentially signaling the company’s direction for the next decade.